Nektar Therapeutics (NKTR) Non-Current Deffered Revenue (2010 - 2020)

Nektar Therapeutics' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $2.5 million for Q4 2020.

• On a quarterly basis, Non-Current Deffered Revenue fell 3.52% year-over-year to $2.5 million in Q4 2020; TTM through Dec 2020 was $2.5 million, a 3.52% decrease from a year earlier, with the FY2020 full-year figure at $2.5 million, down 3.52% from the prior year.
• Non-Current Deffered Revenue retreated to $2.5 million in Q4 2020 per NKTR's latest filing, from $2.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $60.1 million in Q2 2016 and bottomed at $2.5 million in Q4 2020.
• The 5-year median for Non-Current Deffered Revenue is $12.1 million (2018), against an average of $24.5 million.
• Across the five-year window, Non-Current Deffered Revenue dropped 1.51% in 2017 and sank 79.71% in 2018, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $51.9 million in 2016, then tumbled by 63.34% to $19.0 million in 2017, then sank by 43.52% to $10.7 million in 2018, then slumped by 76.23% to $2.6 million in 2019, then fell by 3.52% to $2.5 million in 2020.
• Per Business Quant, the three latest NKTR Non-Current Deffered Revenue figures stand at $2.5 million (Q4 2020), $2.5 million (Q3 2020), and $2.5 million (Q2 2020).